|
Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer
RECRUITINGN/ASponsored by Fondazione IRCCS Policlinico San Matteo di Pavia
Actively Recruiting
PhaseN/A
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
Started2023-06-01
Est. completion2026-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05384873
Summary
The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counseling
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Confirmed histological diagnosis of metastatic non-small cell lung cancer (both squamous and non-squamous histology); * First-line treatment with immunotherapy (alone or in combination with chemotherapy) for metastatic disease by investigators' choice within the framework of good clinical practice and in agreement with current guidelines; * Will to participate by providing written informed consent; * Availability to administer oral supplements and immunotherapy with or without chemotherapy; * Eastern Cooperative Oncology Group Performance Status ≤ 2; * Life expectancy ≥ 6 months. Exclusion Criteria: * Age \< 18 years; * Inability to sign an informed consent; * Indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume oral nutritional supplements
Conditions3
CancerLung CancerLung Cancer, Nonsmall Cell
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
Started2023-06-01
Est. completion2026-07-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05384873